Benzgalantamine

CHEMBL5095056 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.5 g/mol
LogP
4.1
Phase
4

A prodrug of galantamine, an acetylcholinesterase inhibitor used in Alzheimer's disease that works by preventing the breakdown of acetylcholine in the brain, improving memory and cognitive function.

Molekularmasse

391,5000 g/mol

LogP

4,10

TPSA

48,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2

InChI

InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1

Molecular Formula

C24H25NO4

HBD / HBA

- / 5

Rotierbare Bindungen

4

Schwere Atome

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A prodrug of galantamine, an acetylcholinesterase inhibitor used in Alzheimer's disease that works by preventing the breakdown of acetylcholine in the brain, improving memory and cognitive function.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Benzgalantamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095056. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 44240142. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.